secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001326190-25-000053
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune appoints Christophe Arbet-Engels as CMO; Dr. Scott Harris to retire as Senior Strategic Advisor by Feb 2026
--------------------------------------------------------------------------------

- Dr. Scott Harris stepped down as CMO effective Oct 1, 2025; will serve as Senior Strategic Advisor until retirement on Feb 28, 2026.
- Christophe Arbet-Engels, MD, PhD joined as CMO effective Oct 1, 2025.
- Transition Agreement provides Harris continued salary, benefits, equity vesting, and FY2025 bonus eligibility subject to release and compliance.
- Harris's stock option exercise period extended to 12 months after separation date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000053/0001326190-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000053/alt-20251001x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer